034940 — ChoA Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩31bn
- KR₩54bn
- KR₩63bn
- 12
- 46
- 18
- 11
Annual income statement for ChoA Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 65,360 | 57,561 | 68,880 | 62,974 | 62,694 |
| Cost of Revenue | |||||
| Gross Profit | 26,408 | 20,309 | 26,242 | 23,761 | 21,199 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 68,076 | 66,501 | 69,469 | 71,798 | 72,393 |
| Operating Profit | -2,716 | -8,940 | -589 | -8,824 | -9,699 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,767 | -7,146 | -424 | -10,934 | -10,031 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,606 | -8,043 | 515 | -11,133 | -10,168 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,319 | -8,044 | 561 | -10,514 | -9,605 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,319 | -8,044 | 561 | -10,514 | -9,605 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -23.1 | -219 | 20.3 | -300 | -310 |
| Dividends per Share |